Blood Pressure Drug Recalled

Teva Pharmaceuticals USA is recalling 181,456 bottles of olmesartan medoxomil and hydrochlorothiazide tablets, 40 mg/25 mg, after samples failed to meet dissolution specifications, according to the January 23, 2019, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects:

• 30-count bottles (NDC 0093-7617-56) from lots 49O005, 49O006, 49O007, and 49O010 (Exp. 2/19); and
• 90-count bottles (NDC 0093-7617-98) from lots  49O005, 49O009, and 49O010 (Exp. 2/19).

The recalled bottles were distributed throughout the United States.

Teva Pharmaceuticals voluntarily initiated the recall December 19, 2018. On January 16, 2019, the FDA designated it Class II. Drugs affected by Class II recalls may cause temporary or medically reversible adverse health consequences if used. While remote, a possibility of serious harm also exists.

Available with a prescription, olmesartan medoxomil and hydrochlorothiazide is a combination angiotensin II receptor antagonist and thiazide diuretic used to treat patients with hypertension.

—Jolynn Tumolo

For more Pharmacy Learning Network articles, visit the homepage